

For immediate release Seinäjoki, Finland 24.06.2022

Eevia Health Plc has secured a credit line of SEK 8 million for working capital purposes to finance continued growth

Eevia Health Plc, ("Eevia" or "The Company"), has entered into an agreement whereby Exelity AB, Sweden will provide a credit line for Eevia of up to SEK 8 million, giving the Company increased working capital flexibility to finance its continued growth.

The term of the Credit is until December 31, 2022. It is unsecured. Interest is charged at one point five (1.5) percent per month and a five (5) percent arrangement fee.

Stein Ulve, Chief Executive Officer states: "Eevia has experienced significant improvements in production efficiency in the second quarter this year. We are now in a strong operational position and will increase our external focus on customer acquisition and profitable sales growth. The credit line provides for short-term working capital to continue with our strategic focus on expanding the business."

This disclosure contains information that EEVIA HEALTH PLC is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on June 24, 2022.

For further information, please contact:

Stein Ulve, CEO, Eevia Health Plc Email: stein.ulve@eeviahealth.com

Telephone: +358 400 22 5967

Gabriella Beni, CFO, Eevia Health Plc gabriella@eeviahealth.com +358 407 48 8666



INFORMATION ABOUT EEVIA HEALTH PLC

Eevia Health Plc, founded in March 2017, addresses significant health problems with bioactive compounds extracted from plant materials. The materials are primarily wild harvested from the pristine Finnish and Swedish forests near or above the Arctic Circle. The extracts are sold B2B as ingredients to dietary supplements and food brands globally. These global brands utilize the ingredients in their consumer product formulas.

Eevia Health is a manufacturer of 100% organically certified plant extracts. Although a significant product, Elderberry extract, is made from cultivated berries, most of Eevia's other raw materials, such as bilberry, lingonberry, chaga-mushroom, and pine bark, are wild-harvested in a sustainable fashion.

Eevia Health operates a modern green-chemistry production facility in Finland. Manufacturing natural ingredients near the raw material harvest areas, Eevia offers a short value chain with an environmentally friendly carbon footprint, competitive pricing, and extreme transparency. Eevia listed its shares at Spotlight Stock Market in Sweden in June 2021, with the short name EEVIA.

To learn more, please visit www.eeviahealth.com or follow Eevia Health on LinkedIn @EeviaHealth.